Price/Sales of RadNet, Inc.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. It owns and/or operates 305 outpatient imaging centers located in California, Maryland, Delaware, New Jersey, New York, and Rhode Island. The company was founded in 1981 and is headquartered in Los Angeles, California.
|Company||Industry||Est. EPS Q/Q|
|COHR Coherent, Inc.||NASDAQ > Capital Goods > Biotechnology: Laboratory Analytical Instruments||36.96%|
|SIVB SVB Financial Group||NASDAQ > Finance > Major Banks||37.04%|
|EQIX Equinix, Inc.||NASDAQ > Consumer Services > Real Estate Investment Trusts||37.21%|
|ADI Analog Devices, Inc.||NASDAQ > Technology > Semiconductors||37.23%|
|RRD R.R. Donnelley & Sons Company||NASDAQ > Miscellaneous > Publishing||37.25%|
|CIT CIT Group Inc (DEL)||NYSE > Finance > Finance: Consumer Services||37.29%|
|RDNT RadNet, Inc.||NASDAQ > Health Care > Medical Specialities||37.50%|
|CQH Cheniere Energy Partners LP Holdings, LLC||NYSEMKT > Public Utilities > Oil/Gas Transmission||2,100.00%|
|ACOR Acorda Therapeutics, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||2,120.00%|
|CG The Carlyle Group L.P.||NASDAQ > Finance > Investment Managers||2,600.00%|
|OZM Och-Ziff Capital Management Group LLC||NYSE > Finance > Investment Managers||2,800.00%|
|ALDW Alon USA Partners, LP||NYSE > Energy > Integrated oil Companies||4,600.00%|
|ANDV Andeavor||NYSE > Energy > Integrated oil Companies||4,866.67%|